Back to Search Start Over

Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma

Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma

Authors :
Kaori Kuramitsu
Masahiro Kido
Hiroaki Yanagimoto
Hidetoshi Gon
Kenji Fukushima
Takeshi Urade
Yuzo Kodama
Shinichi So
Shohei Komatsu
Hirochika Toyama
Takumi Fukumoto
Yoshihiko Yano
Source :
Anticancer research. 41(9)
Publication Year :
2021

Abstract

Background/aim While there is increasing evidence supporting the role of several first- and second-line treatment regimens for advanced hepatocellular carcinomas (HCC), the clinical relevance of rechallenge treatment with previously administered drugs, however, remains to be explored. Patients and methods Five consecutive patients with advanced HCC who received lenvatinib rechallenge treatment after ramucirumab were assessed. Results All patients were clinically diagnosed with failure after ramucirumab treatment, and the frequencies of ramucirumab administration before lenvatinib re-administration ranged from 3 to 11. The alfa-fetoprotein level in four of five patients decreased 1 month after the lenvatinib rechallenge. Radiological findings via the modified Response Evaluation Criteria in Solid Tumors showed stable diseases in four patients and a partial response in one. Conclusion Rechallenge treatment with lenvatinib after ramucirumab can be effective, and may be a treatment option for HCC in cases wherein the disease progressed after an initial response to lenvatinib treatment.

Details

ISSN :
17917530
Volume :
41
Issue :
9
Database :
OpenAIRE
Journal :
Anticancer research
Accession number :
edsair.doi.dedup.....0ca4e0b7670c1d1eee2c688f61d36054